Moderna 8-K Signals Upcoming Financial Disclosure

TL;DR

**Moderna just filed an 8-K, expect new financial results soon!**

AI Summary

Moderna, Inc. filed an 8-K on January 8, 2024, to report an event related to its 'Results of Operations and Financial Condition' and 'Regulation FD Disclosure'. This filing indicates that Moderna is providing an update on its financial performance, likely in preparation for an upcoming investor presentation or earnings call. For investors, this matters because it signals that new financial information about Moderna's operations will be disclosed, which could impact the stock's valuation and future outlook.

Why It Matters

This filing indicates Moderna is about to release new financial information, which could significantly influence investor perception and stock price.

Risk Assessment

Risk Level: low — This 8-K is a procedural filing indicating upcoming financial disclosures, not a disclosure of negative events itself.

Analyst Insight

A smart investor would monitor Moderna's news channels closely for the actual financial disclosure that this 8-K foreshadows, as that will contain the actionable information.

Key Players & Entities

• Moderna, Inc. (company) — the registrant filing the 8-K
• January 8, 2024 (date) — date of earliest event reported and filing date
• 001-38753 (other) — Moderna's Commission File Number
• MRNA (other) — Moderna's trading symbol on Nasdaq

Forward-Looking Statements

• Moderna will release detailed financial results or guidance soon. (Moderna, Inc.) — high confidence, target: Q1 2024
• The upcoming financial disclosure will likely be part of an investor presentation or earnings call. (Moderna, Inc.) — high confidence, target: Q1 2024

FAQ

Key Financial Figures

• $0.0001 — ich registered Common stock, par value $0.0001 per share MRNA The Nasdaq Stock Market
• $6.7 billion — (i) the Company generated approximately $6.7 billion in product sales (unaudited) for the fi
• $0.6 billion — including recognition of approximately $0.6 billion of deferred revenue related to the Comp
• $13 billion — of December 31, 2023 were in excess of $13 billion. The information in this Item 2.02 is

Filing Documents

• mrna-20240108.htm (8-K) — 31KB
• exhibit991-01082024jpm.htm (EX-99.1) — 24KB
• 0001682852-24-000004.txt ( ) — 185KB
• mrna-20240108.xsd (EX-101.SCH) — 2KB
• mrna-20240108_lab.xml (EX-101.LAB) — 23KB
• mrna-20240108_pre.xml (EX-101.PRE) — 12KB
• mrna-20240108_htm.xml (XML) — 3KB

02 Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition. On January 8, 2024 , Moderna, Inc. (the "Company") issued a press release (the "Press Release") in connection with the Company's presentation on the same date at the 42nd Annual J.P. Morgan Healthcare Conference. The Press Release contains certain preliminary financial information as of and for the fiscal year ended December 31, 2023. Specifically, the Press Release states that (i) the Company generated approximately $6.7 billion in product sales (unaudited) for the fiscal year ended December 31, 2023 from sales of its COVID-19 vaccine, including recognition of approximately $0.6 billion of deferred revenue related to the Company's efforts with GAVI, The Vaccine Alliance, and (ii) the Company's current expectation with respect to its cash, cash equivalents and investments in marketable securities (unaudited) as of December 31, 2023 were in excess of $13 billion. The information in this Item 2.02 is unaudited and preliminary, and does not present all information necessary for an understanding of the Company's results of operations for the fiscal year ended December 31, 2023, or financial condition as of December 31, 2023. The audit of the Company's financial statements for the year ended December 31, 2023 is ongoing and could result in changes to the information in this Item 2.02.

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. The disclosure in Item 2.02 above is hereby incorporated by reference into this Item 7.01. The information contained in Items 2.02 and 7.01, as well as Exhibit 99.1, to this Current Report on Form 8-K shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press release by Moderna, Inc. dated January 8, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: January 8, 2024 MODERNA, INC. By: /s/ Shannon Thyme Klinger Shannon Thyme Klinger Chief Legal Officer

View Full Filing

View this 8-K filing on SEC EDGAR